<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38154880</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Characterisation of internal tremors and vibration symptoms.</ArticleTitle><Pagination><StartPage>e077389</StartPage><MedlinePgn>e077389</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e077389</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-077389</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To describe the experiences of patients who have postacute sequelae SARS-CoV-2 infection with internal vibrations and tremors as a prominent component, we leveraged the efforts by Survivor Corps, a grassroots COVID-19 patient advocacy group, to gather information from individuals belonging to its Facebook group with a history of COVID-19 suffering from vibrations and tremors.</AbstractText><AbstractText Label="SETTING AND DESIGN">A narrative analysis was performed on 140 emails and 450 social media comments from 140 individuals collected as a response to a call to &gt;180 000 individuals participating in Survivor Corps between 15 July and 27 July 2021. We used common coding techniques and the constant comparative method for qualitative data synthesis and categorising emails. Coded data were entered into NVivo V.12 to identify recurrent themes, theme connections and supporting quotations. Comments were analysed using Word Clouds, generated with R V.4.0.3 using <i>quanteda</i>, <i>wordcloud</i> and <i>tm</i> packages.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Patient-reported long COVID symptom themes and domains related to internal tremors and vibration.</AbstractText><AbstractText Label="RESULTS">The respondents' emails represented 22 themes and 7 domains pertaining to their experience with internal tremor and vibrations. These domains were as follows: (1) symptom experience, description and anatomic location; (2) initial symptom onset; (3) symptom timing; (4) symptom triggers or alleviators; (5) change from baseline health status; (6) experience with medical establishment and (7) impact on individuals' lives and livelihood. There were 22 themes in total, each corresponding to one of the broader domains. Among the responses, many described symptoms that varied in location, timing and triggers, occurred soon after their COVID-19 infection, and were markedly debilitating. There were often frustrating experiences with the healthcare system.</AbstractText><AbstractText Label="CONCLUSIONS">This study describes key themes and experiences among a group of people reporting long COVID and having a prolonged and debilitating symptom complex that prominently features internal tremors and vibrations.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massey</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawano</LastName><ForeName>Mitsuaki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2789-1758</Identifier><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Anna D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Section of Stroke and Vascular Neurology, Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;the</LastName><ForeName>Diana Berrent</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Survivor Corps, Washington, DC, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;the</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Survivor Corps, Washington, DC, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shidlovsky</LastName><ForeName>Suzanne Pincus</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Survivor Corps, Washington, DC, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Liza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Survivor Corps, Washington, DC, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grady</LastName><ForeName>Connor B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caraballo</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4557-9437</Identifier><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Tianna</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Richa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0003-2046-127X</Identifier><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale University, New Haven, Connecticut, USA harlan.krumholz@yale.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Infection and Immunity, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014732" MajorTopicYN="N">Vibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NEUROLOGY</Keyword><Keyword MajorTopicYN="N">REGISTRIES</Keyword></KeywordList><CoiStatement>Competing interests: In the past 3 years, Dr Krumholz reported receiving personal fees from Massachusetts Medical Society, UpToDate, Element Science, Eyedentify and F-Prime. He is a cofounder of HugoHealth, Refactor Health and Ensight-AI. He is associated with grants and/or contracts, through Yale New Haven Hospital, from the Centers for Medicare &amp; Medicaid Services and through Yale University from Johnson &amp; Johnson Consumer, Janssen and Pfizer. The other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>3</Day><Hour>8</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>29</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>28</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38154880</ArticleId><ArticleId IdType="pmc">PMC10759066</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-077389</ArticleId><ArticleId IdType="pii">bmjopen-2023-077389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of Postacute sequelae of SARS-Cov-2 infection: a systematic review. JAMA Netw Open 2021;4:e2128568. 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. . Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 2021;397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. . Development of a definition of Postacute sequelae of SARS-Cov-2 infection. JAMA 2023;329:1934&#x2013;46. 10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Przytu&#x142;a F, B&#x142;&#x105;dek S, S&#x142;awek J. Two COVID-19-related Video-accompanied cases of severe ataxia-myoclonus syndrome. Neurol Neurochir Pol 2021;55:310&#x2013;3. 10.5603/PJNNS.a2021.0036</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/PJNNS.a2021.0036</ArticleId><ArticleId IdType="pubmed">34096013</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, et al. . Reversible myoclonus-ataxia as a Postinfectious manifestation of COVID-19. Mov Disord Clin Pract 2020;7:977&#x2013;9. 10.1002/mdc3.13088</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13088</ArticleId><ArticleId IdType="pmc">PMC7604679</ArticleId><ArticleId IdType="pubmed">33163570</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamikhah M, Babadi M, Mehrabani M, et al. . Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol 2021;27:26&#x2013;34. 10.1007/s13365-020-00941-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-020-00941-1</ArticleId><ArticleId IdType="pmc">PMC7831695</ArticleId><ArticleId IdType="pubmed">33492608</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome in the setting of COVID-19 infection. Neurology 2021;96:33. 10.1212/WNL.0000000000010978</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010978</ArticleId><ArticleId IdType="pubmed">33004603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkstra F, Van den T, Willekens B, et al. . Myoclonus and cerebellar ataxia following Coronavirus disease 2019 (COVID-19). Mov Disord Clin Pract 2020;7:974&#x2013;6. 10.1002/mdc3.13049</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13049</ArticleId><ArticleId IdType="pmc">PMC7436437</ArticleId><ArticleId IdType="pubmed">32837962</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi S, Lagarde S, Harl&#xe9; J-R, et al. . Autoimmune encephalitis concomitant with SARS-Cov-2 infection: insight from (18)F-FDG PET imaging and neuronal Autoantibodies . J Nucl Med 2020;61:1726&#x2013;9. 10.2967/jnumed.120.249292</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.249292</ArticleId><ArticleId IdType="pmc">PMC8679632</ArticleId><ArticleId IdType="pubmed">32709734</ArticleId></ArticleIdList></Reference><Reference><Citation>Foucard C, San-Galli A, Tarrano C, et al. . Acute cerebellar ataxia and myoclonus with or without Opsoclonus: a para-infectious syndrome associated with COVID-19. Eur J Neurol 2021;28:3533&#x2013;6. 10.1111/ene.14726</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14726</ArticleId><ArticleId IdType="pmc">PMC8013847</ArticleId><ArticleId IdType="pubmed">33492711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright D, Rowley R, Halks-Wellstead P, et al. . Abnormal Saccadic Oscillations associated with severe acute respiratory syndrome Coronavirus 2 encephalopathy and ataxia. Mov Disord Clin Pract 2020;7:980&#x2013;2. 10.1002/mdc3.13101</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13101</ArticleId><ArticleId IdType="pmc">PMC7604668</ArticleId><ArticleId IdType="pubmed">33163571</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review. J Neurol 2021;268:3517&#x2013;48. 10.1007/s00415-021-10458-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10458-0</ArticleId><ArticleId IdType="pmc">PMC7897737</ArticleId><ArticleId IdType="pubmed">33616739</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Corte M, Delehaye C, Savastano E, et al. . Neuropsychiatric syndrome with myoclonus after SARS-Cov-2 infection in a Paediatric patient. Clin Neurol Neurosurg 2022;213:107121. 10.1016/j.clineuro.2022.107121</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2022.107121</ArticleId><ArticleId IdType="pmc">PMC8739821</ArticleId><ArticleId IdType="pubmed">35030418</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand P, Zakaria A, Benameur K, et al. . Myoclonus in patients with Coronavirus disease 2019: A multicenter case series. Crit Care Med 2020;48:1664&#x2013;9. 10.1097/CCM.0000000000004570</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004570</ArticleId><ArticleId IdType="pmc">PMC7448712</ArticleId><ArticleId IdType="pubmed">32804787</ArticleId></ArticleIdList></Reference><Reference><Citation>Massey D, Berrent D, Krumholz H. Breakthrough symptomatic COVID-19 infections leading to long COVID: report from long COVID facebook group poll. Epidemiology [Preprint]. 10.1101/2021.07.23.21261030</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.23.21261030</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert NJ, Survivor Corps . &#x2018;COVID-19&#x2018;long Hauler&#x2019; symptoms survey report 2020&#x2019;. n.d.
Available: https://dig.abclocal.go.com/wls/documents/2020/072720-wls-covid-symptom-study-doc.pdf</Citation></Reference><Reference><Citation>Lambert N, Corps S, El-Azab SA, et al. . COVID-19 survivors&#x2019; reports of the timing, duration, and health impacts of post-acute sequelae of SARS-cov-2 (PASC) infection. Infectious Diseases (except HIV/AIDS) [Preprint]. 10.1101/2021.03.22.21254026</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.22.21254026</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree BF, Miller WL. Doing qualitative research. Thousand Oaks, Calif: Sage Publications, 1999: 406.</Citation></Reference><Reference><Citation>Miles MB, Huberman AM. Qualitative data analysis:An expanded sourcebook. Thousand Oaks: Sage Publications, 1994.</Citation></Reference><Reference><Citation>Benoit K, Watanabe K, Wang H, et al. . An R package for the quantitative analysis of textual data. JOSS 2018;3:774. 10.21105/joss.00774</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.00774</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinerer I, Hornik K, Meyer D. Text mining infrastructure in R. J Stat Softw 2008;25:1&#x2013;54. 10.18637/jss.v025.i05</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v025.i05</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasnier M, Choucha W, Radiguer F, et al. . Comorbidity of long COVID and psychiatric disorders after a Hospitalisation for COVID-19: a cross-sectional study. J Neurol Neurosurg Psychiatry 2022. 10.1136/jnnp-2021-328516</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328516</ArticleId><ArticleId IdType="pubmed">35953265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Quan L, Chavarro JE, et al. . Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry 2022;79:1081&#x2013;91. 10.1001/jamapsychiatry.2022.2640</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.2640</ArticleId><ArticleId IdType="pmc">PMC9453634</ArticleId><ArticleId IdType="pubmed">36069885</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with COVID-19: cohort study. BMJ 2022;376:e068993. 10.1136/bmj-2021-068993</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068993</ArticleId><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>